Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?

被引：42

作者：

Correale, Michele ^{[1
]}

Ferraretti, Armando ^{[2
]}

Monaco, Ilenia ^{[3
]}

Grazioli, Davide ^{[1
]}

Di Biase, Matteo ^{[4
]}

Brunetti, Natale Daniele ^{[3
]}

机构：

[1] Osped Riuniti Univ Hosp, Dept Cardiol, Foggia, Italy

[2] Caduti Guerra Hosp, Cardiol Unit, Canosa Di Puglia, BT, Italy

[3] Univ Foggia, Dept Cardiol, Foggia, Italy

[4] Santa Maria Hosp, GVM Care & Res, Bari, Italy

来源：

VASCULAR HEALTH AND RISK MANAGEMENT | 2018年 / 14卷

关键词：

endothelin-receptor antagonists; pulmonary arterial hypertension; Bosentan; ambrisentan; sitaxentan; macitentan;

D O I：

10.2147/VHRM.S133921

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Pulmonary arterial hypertension, a disease largely neglected until a few decades ago, is presently the object of intense studies by several research teams. Despite considerable progress, pulmonary arterial hypertension remains a major clinical problem, because it is not always easy to diagnose, treat, and prevent. The disease was considered incurable until the late 1990s, when Epoprostenol was introduced as the first tool against this illness. More recently, therapy for pulmonary arterial hypertension gained momentum after publication of the SERAPHIN and AMBITION trials, which also highlighted the importance of upfront therapy. This review also focuses on recent substudies from these trials and progress in drugs targeting the endothelin pathway. Future perspectives with regard to endothelin-receptor antagonists are also discussed.

引用

页码：253 / 264

页数：12

共 78 条

[1]

Actelion Pharmaceuticals, 2016, OPS MAC TABL OR US P

[2] Pharmacokinetic-Pharmacodynamic Relationships of Macitentan, a New Endothelin Receptor Antagonist, After Multiple Dosing in Healthy Korean Subjects [J].

Ahn, Li Young ;

Kim, Sung Eun ;

Yi, SoJeong ;

Dingemanse, Jasper ;

Lim, Kyoung Soo ;

Jang, In-Jin ;

Yu, Kyung-Sang .

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (05) :377-385

[3] Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects [J].

Atsmon, Jacob ;

Dingemanse, Jasper ;

Shaikevich, Dimitri ;

Volokhov, Inna ;

Sidharta, Patricia N. .

CLINICAL PHARMACOKINETICS, 2013, 52 (08) :685-692

[4] ARIES-3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension [J].

Badesch, David B. ;

Feldman, Jeremy ;

Keogh, Anne ;

Mathier, Michael A. ;

Oudiz, Ronald J. ;

Shapiro, Shelley ;

Farber, Harrison W. ;

McGoon, Michael ;

Frost, Adaani ;

Allard, Martine ;

Despain, Darrin ;

Dufton, Christopher ;

Rubin, Lewis J. .

CARDIOVASCULAR THERAPEUTICS, 2012, 30 (02) :93-99

[5] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[6] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[7] Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan [J].

Benza, Raymond L. ;

Mehta, Sanjay ;

Keogh, Anne ;

Lawrence, E. Clinton ;

Oudiz, Ronald J. ;

Barst, Robyn J. .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (01) :63-69

[8] From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement? [J].

Blok, Ilja M. ;

van Riel, Annelieke C. M. J. ;

van Dijk, Arie P. J. ;

Mulder, Barbara J. M. ;

Bouma, Berto J. .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 227 :51-52

[9] The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist [J].

Bolli, Martin H. ;

Boss, Christoph ;

Binkert, Christoph ;

Buchmann, Stephan ;

Bur, Daniel ;

Hess, Patrick ;

Iglarz, Marc ;

Meyer, Solange ;

Rein, Josiane ;

Rey, Markus ;

Treiber, Alexander ;

Clozel, Martine ;

Fischli, Walter ;

Weller, Thomas .

JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (17) :7849-7861

[10] Pharmacokinetics of Macitentan in Caucasian and Japanese Subjects: The Influence of Ethnicity and Sex [J].

Bruderer, Shirin ;

Marjason, Joanne ;

Sidharta, Patricia N. ;

Dingemanse, Jasper .

PHARMACOLOGY, 2013, 91 (5-6) :331-338

← 1 2 3 4 5 6 7 8 →